Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01307423
Registration number
NCT01307423
Ethics application status
Date submitted
29/11/2010
Date registered
2/03/2011
Titles & IDs
Public title
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
Query!
Scientific title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis Who Have Not Been Previously Treated With Disease-modifying Antirheumatic Drugs
Query!
Secondary ID [1]
0
0
2010-020324-22
Query!
Secondary ID [2]
0
0
CC-10004-PSA-005
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
PALACE4
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Psoriatic Arthritis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Apremilast 20mg
Treatment: Drugs - Apremilast 30mg
Treatment: Drugs - Placebo
Experimental: Apremilast 20mg - Apremilast 20mg twice daily, orally
Experimental: Apremilast 30mg - Apremilast 30mg twice daily, orally
Placebo comparator: Placebo + 20mg Apremilast - Placebo + 20mg Apremilast tablets administered twice daily
Placebo comparator: Placebo + 30mg Apremilast - Placebo + 30mg Apremilast tablets administered twice daily
Treatment: Drugs: Apremilast 20mg
Apremilast 20mg twice daily, orally
Treatment: Drugs: Apremilast 30mg
Apremilast 30mg twice daily, orally
Treatment: Drugs: Placebo
Placebo
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16
Query!
Assessment method [1]
0
0
A participant was a responder if the following 3 criteria for improvement from Baseline were met: • = 20% improvement in 78 tender joint count; • = 20% improvement in 76 swollen joint count; and • = 20% improvement in at least 3 of the 5 following parameters: -Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); -Patient's global assessment of disease activity (measured on a 100 mm VAS); -Physician's global assessment of disease activity (measured on a 100 mm VAS); -Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); -C-Reactive Protein.
Query!
Timepoint [1]
0
0
Baseline and Week 16
Query!
Secondary outcome [1]
0
0
Change From Baseline in Health Assessment Questionnaire- Disability Index [HAQ-DI]) at Week 16
Query!
Assessment method [1]
0
0
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative changes from baseline in the overall score indicate improvement in functional ability.
Query!
Timepoint [1]
0
0
Baseline and Week 16
Query!
Secondary outcome [2]
0
0
Percentage of Participants With an ACR 20 Response at Week 24
Query!
Assessment method [2]
0
0
Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from baseline were met: • = 20% improvement in 78 tender joint count; • = 20% improvement in 76 swollen joint count; and • = 20% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.
Query!
Timepoint [2]
0
0
Baseline and Week 24
Query!
Secondary outcome [3]
0
0
Change From Baseline in Health Assessment Questionnaire- Disability Index [HAQ-DI]) at Week 24
Query!
Assessment method [3]
0
0
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative changes from Baseline in the overall score indicate improvement in functional ability.
Query!
Timepoint [3]
0
0
Baseline and Week 24
Query!
Secondary outcome [4]
0
0
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16
Query!
Assessment method [4]
0
0
The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). SF-36 domain scores were first calculated to range from 0 to100 and then transformed to norm-based scores (the norm-based scores in the US general population have an average of 50 and a standard deviation of 10). Norm-based scores were used in analyses, with higher scores indicating a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from baseline score indicates an improvement.
Query!
Timepoint [4]
0
0
Baseline and Week 16
Query!
Secondary outcome [5]
0
0
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16
Query!
Assessment method [5]
0
0
Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0=lowest disease activity and 100=highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0=lowest disease activity and 100=highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by = 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by = 20 mm VAS.
Query!
Timepoint [5]
0
0
Baseline and Week 16
Query!
Secondary outcome [6]
0
0
Change From Baseline in Patient's Assessment of Pain at Week 16
Query!
Assessment method [6]
0
0
The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.
Query!
Timepoint [6]
0
0
Baseline and Week 16
Query!
Secondary outcome [7]
0
0
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16
Query!
Assessment method [7]
0
0
The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
Query!
Timepoint [7]
0
0
Baseline and Week 16
Query!
Secondary outcome [8]
0
0
Change From Baseline in Dactylitis Severity Score at Week 16
Query!
Assessment method [8]
0
0
Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
Query!
Timepoint [8]
0
0
Baseline to Week 16
Query!
Secondary outcome [9]
0
0
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16
Query!
Assessment method [9]
0
0
The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: = 2.8 Low Disease Activity: \> 2.8 and = 10 Moderate Disease Activity: \> 10 and = 22 High Disease Activity: \> 22
Query!
Timepoint [9]
0
0
Baseline and Week 16
Query!
Secondary outcome [10]
0
0
Change From Baseline in the Disease Activity Score (DAS28) After 16 Weeks of Treatment
Query!
Assessment method [10]
0
0
The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.
Query!
Timepoint [10]
0
0
Baseline and Week 16
Query!
Secondary outcome [11]
0
0
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16
Query!
Assessment method [11]
0
0
The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.
Query!
Timepoint [11]
0
0
Baseline and Week 16
Query!
Secondary outcome [12]
0
0
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 24
Query!
Assessment method [12]
0
0
The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). SF-36 domain scores were first calculated to range from 0 to100 and then transformed to norm-based scores (the norm-based scores in the US general population have an average of 50 and a standard deviation of 10). Norm-based scores were used in analyses, with higher scores indicating a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from baseline score indicates an improvement.
Query!
Timepoint [12]
0
0
Baseline and Week 24
Query!
Secondary outcome [13]
0
0
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24
Query!
Assessment method [13]
0
0
Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0=lowest disease activity and 100=highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0=lowest disease activity and 100=highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by = 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by = 20 mm VAS.
Query!
Timepoint [13]
0
0
Baseline and Week 24
Query!
Secondary outcome [14]
0
0
Change From Baseline in Participants Assessment of Pain at Week 24
Query!
Assessment method [14]
0
0
The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.
Query!
Timepoint [14]
0
0
Baseline and Week 24
Query!
Secondary outcome [15]
0
0
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24
Query!
Assessment method [15]
0
0
The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
Query!
Timepoint [15]
0
0
Baseline and Week 24
Query!
Secondary outcome [16]
0
0
Change From Baseline in Dactylitis Severity Score at Week 24
Query!
Assessment method [16]
0
0
Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
Query!
Timepoint [16]
0
0
Baseline and Week 24
Query!
Secondary outcome [17]
0
0
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24
Query!
Assessment method [17]
0
0
The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: = 2.8; Low Disease Activity: \> 2.8 and = 10; Moderate Disease Activity: \> 10 and = 22; High Disease Activity: \> 22.
Query!
Timepoint [17]
0
0
Baseline and Week 24
Query!
Secondary outcome [18]
0
0
Change From Baseline in Disease Activity Score (DAS 28) at Week 24
Query!
Assessment method [18]
0
0
The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.
Query!
Timepoint [18]
0
0
Baseline and Week 24
Query!
Secondary outcome [19]
0
0
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24
Query!
Assessment method [19]
0
0
The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.
Query!
Timepoint [19]
0
0
Baseline and Week 24
Query!
Secondary outcome [20]
0
0
Percentage of Participants With = 20% Improvement in Maastricht Ankylosing Spondylitis Entheses Score at Week 16
Query!
Assessment method [20]
0
0
Percentage of participants with pre-existing enthesopathy whose MASES improved by = 20% from Baseline after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
Query!
Timepoint [20]
0
0
Baseline and Week 16
Query!
Secondary outcome [21]
0
0
Percentage of Participants With Dactylitis Improvement = 1 Point at Week 16
Query!
Assessment method [21]
0
0
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by = 1 after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
Query!
Timepoint [21]
0
0
Baseline and Week 16
Query!
Secondary outcome [22]
0
0
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16
Query!
Assessment method [22]
0
0
The EULAR response criteria classify each subject as a good, moderate or non-responder to treatment based on the degree of improvement from baseline and the level of disease activity at the endpoint. EULAR response is derived using the individual subject's DAS28 as the measure of severity of disease. Good or moderate response is defined as follows: Good response: DAS28 at the time point = 3.2 and improvement from baseline \> 1.2 Moderate response: DAS28 at the time point \> 3.2 and improvement from baseline \> 1.2, or DAS28 at the time point = 5.1 and improvement from baseline \> 0.6 and = 1.2
Query!
Timepoint [22]
0
0
Baseline and Week 16
Query!
Secondary outcome [23]
0
0
Percentage of Participants With MASES Improvement = 20% at Week 24
Query!
Assessment method [23]
0
0
Percentage of participants with pre-existing enthesopathy whose MASES improved by = 20% from Baseline after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
Query!
Timepoint [23]
0
0
Baseline and Week 24
Query!
Secondary outcome [24]
0
0
Percentage of Participants With Dactylitis Improvement = 1 Point at Week 24
Query!
Assessment method [24]
0
0
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by = 1 after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
Query!
Timepoint [24]
0
0
Baseline and Week 24
Query!
Secondary outcome [25]
0
0
Percentage of Participants With Good or Moderate EULAR Response at Week 24
Query!
Assessment method [25]
0
0
The EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on th DAS-28. Good or moderate response is defined as follows: Good response: DAS28 at the time point = 3.2 and improvement from baseline \> 1.2 Moderate response: DAS28 at the time point \> 3.2 and improvement from baseline \> 1.2, or DAS28 at the time point = 5.1 and improvement from baseline \> 0.6 and = 1.2 A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.
Query!
Timepoint [25]
0
0
Baseline and Week 24
Query!
Secondary outcome [26]
0
0
Percentage of Participants With a ACR 50 Response at Week 16
Query!
Assessment method [26]
0
0
Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • = 50% improvement in 78 tender joint count; • = 50% improvement in 76 swollen joint count; and • = 50% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.
Query!
Timepoint [26]
0
0
Baseline and Week 16
Query!
Secondary outcome [27]
0
0
Percentage of Participants With a ACR 70 Response at Week 16
Query!
Assessment method [27]
0
0
Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • = 70% improvement in 78 tender joint count; • = 70% improvement in 76 swollen joint count; and • = 70% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.
Query!
Timepoint [27]
0
0
Baseline and Week 16
Query!
Secondary outcome [28]
0
0
Percentage of Participants With a ACR 50 Response at Week 24
Query!
Assessment method [28]
0
0
Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • = 50% improvement in 78 tender joint count; • = 50% improvement in 76 swollen joint count; and • = 50% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.
Query!
Timepoint [28]
0
0
Baseline and Week 24
Query!
Secondary outcome [29]
0
0
Percentage of Participants With a ACR 70 Response at Week 24
Query!
Assessment method [29]
0
0
Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • = 70% improvement in 78 tender joint count; • = 70% improvement in 76 swollen joint count; and • = 70% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.
Query!
Timepoint [29]
0
0
Baseline and Week 24
Query!
Secondary outcome [30]
0
0
Percentage of Participants With Pre-existing Enthesopathy Whose Maastricht Ankylosing Spondylitis Entheses Score Improves to 0 at Week 16
Query!
Assessment method [30]
0
0
Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
Query!
Timepoint [30]
0
0
Baseline and Week 16
Query!
Secondary outcome [31]
0
0
Percentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves to 0 at Week 16
Query!
Assessment method [31]
0
0
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
Query!
Timepoint [31]
0
0
Baseline and Week 16
Query!
Secondary outcome [32]
0
0
Percentage of Participants Achieving a MASES Score of Zero at Week 24
Query!
Assessment method [32]
0
0
Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
Query!
Timepoint [32]
0
0
Baseline and Week 24
Query!
Secondary outcome [33]
0
0
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 24
Query!
Assessment method [33]
0
0
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.
Query!
Timepoint [33]
0
0
Baseline and Week 24
Query!
Secondary outcome [34]
0
0
Percentage of Participants With a ACR 20 Response at Week 52
Query!
Assessment method [34]
0
0
Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: = 20% improvement in 78 tender joint count; = 20% improvement in 76 swollen joint count; and = 20% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
Query!
Timepoint [34]
0
0
Baseline and Week 52
Query!
Secondary outcome [35]
0
0
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52
Query!
Assessment method [35]
0
0
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative changes from Baseline in the overall score indicate improvement in functional ability.
Query!
Timepoint [35]
0
0
Baseline and Week 52
Query!
Secondary outcome [36]
0
0
Change From Baseline in the SF-36v2 Physical Functioning Scale Score at Week 52
Query!
Assessment method [36]
0
0
The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.
Query!
Timepoint [36]
0
0
Baseline and Week 52
Query!
Secondary outcome [37]
0
0
Percentage of Participants With a Modified PsARC Response at Week 52
Query!
Assessment method [37]
0
0
Measure Description: Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0=lowest disease activity and 100=highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0=lowest disease activity and 100=highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by = 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by = 20 mm VAS. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
Query!
Timepoint [37]
0
0
Baseline and Week 52
Query!
Secondary outcome [38]
0
0
Change From Baseline in the Participants Assessment of Pain Using the Visual Analog Scale at Week 52
Query!
Assessment method [38]
0
0
The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.
Query!
Timepoint [38]
0
0
Baseline and Week 52
Query!
Secondary outcome [39]
0
0
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52
Query!
Assessment method [39]
0
0
The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.
Query!
Timepoint [39]
0
0
Baseline and Week 52
Query!
Secondary outcome [40]
0
0
Change From Baseline in the Dactylitis Severity Score at Week 52
Query!
Assessment method [40]
0
0
Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present
Query!
Timepoint [40]
0
0
Baseline and Week 52
Query!
Secondary outcome [41]
0
0
Change From Baseline in the CDAI Score at Week 52
Query!
Assessment method [41]
0
0
The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: 28 tender joint count (TJC), 28 swollen joint count (SJC), Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: = 2.8 Low Disease Activity: \> 2.8 and = 10 Moderate Disease Activity: \> 10 and = 22 High Disease Activity: \> 22.
Query!
Timepoint [41]
0
0
Baseline and Week 52
Query!
Secondary outcome [42]
0
0
Change From Baseline in the DAS28 at Week 52
Query!
Assessment method [42]
0
0
The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.
Query!
Timepoint [42]
0
0
Baseline and Week 52
Query!
Secondary outcome [43]
0
0
Change From Baseline in the FACIT-Fatigue Scale Score at Week 52
Query!
Assessment method [43]
0
0
The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.
Query!
Timepoint [43]
0
0
Baseline and Week 52
Query!
Secondary outcome [44]
0
0
Percentage of Participants With MASES Improvement = 20% at Week 52
Query!
Assessment method [44]
0
0
Percentage of participants with pre-existing enthesopathy whose MASES improved by = 20% from Baseline after 52 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
Query!
Timepoint [44]
0
0
Baseline and Week 52
Query!
Secondary outcome [45]
0
0
Percentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves From Baseline by = 1 at Week 52
Query!
Assessment method [45]
0
0
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by = 1 after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
Query!
Timepoint [45]
0
0
Baseline and Week 52
Query!
Secondary outcome [46]
0
0
Percentage of Participants Achieving Good or Moderate EULAR Response at Week 52
Query!
Assessment method [46]
0
0
The EULAR response criteria classify each subject as a good, moderate or non-responder to treatment based on the degree of improvement from baseline and the level of disease activity at the endpoint. EULAR response is derived using the individual subject's DAS28 as the measure of severity of disease. A Good response is defined as follows: Good response: DAS28 at the time point = 3.2 and improvement from baseline \> 1.2 A Moderate Response is defined as either: an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2. Two-sided 95% confidence interval is based on the Clopper-Pearson method
Query!
Timepoint [46]
0
0
Baseline and Week 52
Query!
Secondary outcome [47]
0
0
Percentage of Participants With an ACR 50 Response at Week 52
Query!
Assessment method [47]
0
0
Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: = 50% improvement in 78 tender joint count; = 50% improvement in 76 swollen joint count; and = 50% improvement in at least 3 of the 5 following parameters: o Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
Query!
Timepoint [47]
0
0
Baseline and Week 52
Query!
Secondary outcome [48]
0
0
Percentage of Participants With an ACR 70 Response at Week 52
Query!
Assessment method [48]
0
0
A participant was a responder if the following 3 criteria for improvement from Baseline were met: = 70% improvement in 78 tender joint count; = 70% improvement in 76 swollen joint count; and = 70% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
Query!
Timepoint [48]
0
0
Baseline and Week 52
Query!
Secondary outcome [49]
0
0
Percentage of Participants With Pre-existing Enthesopathy Whose MASES Improves From Baseline to 0 at Week 52
Query!
Assessment method [49]
0
0
Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval was based on the Clopper-Pearson method.
Query!
Timepoint [49]
0
0
Baseline and Week 52
Query!
Secondary outcome [50]
0
0
Percentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves From Baseline to 0 at Week 52
Query!
Assessment method [50]
0
0
Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit and ranges from 0 to 20. Two-sided 95% confidence interval is based on the Clopper-Pearson method.
Query!
Timepoint [50]
0
0
Baseline and Week 52
Query!
Secondary outcome [51]
0
0
Number of Participants With Treatment Emergent Adverse Events During the Placebo Controlled Phase
Query!
Assessment method [51]
0
0
A TEAE is an adverse event (AE) with a start date on or after the date of the first dose of investigational product (IP) and no later than 28 days after the last dose of IP. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. A serious AE is any AE that results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or constitutes an important medical event. For both AEs and SAEs the investigator assessed the severity of the event according to the grading scale: Mild: asymptomatic or with mild symptoms, Moderate: symptoms causing moderate discomfort or Severe: symptoms causing severe discomfort or pain.
Query!
Timepoint [51]
0
0
Week 0 to Week 16 for placebo participants who entered EE at Week 16 and up to Week 24 for all other participants (placebo participants who remained on placebo through week 24 and participants randomized to the APR 20 mg BID or APR 30 mg BID)
Query!
Secondary outcome [52]
0
0
Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period
Query!
Assessment method [52]
0
0
A TEAE is an adverse event (AE) with a start date on or after the date of the first dose of investigational product (IP) and no later than 28 days after the last dose of IP. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. A serious AE is any AE that results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or constitutes an important medical event. For both AEs and SAEs the investigator assessed the severity of the event according to the grading scale: Mild: asymptomatic or with mild symptoms, Moderate: symptoms causing moderate discomfort or Severe: symptoms causing severe discomfort or pain.
Query!
Timepoint [52]
0
0
Week 0 to Week 260; median duration of exposure to apremilast 20 mg BID was 168.93 weeks and 229.36 weeks for apremilast 30 mg BID
Query!
Eligibility
Key inclusion criteria
Subjects must satisfy the following criteria to be enrolled in the study:
1. Male or female, aged = 18 years at time of consent.
2. Must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
3. Able to adhere to the study visit schedule and other protocol requirements.
4. Have a documented diagnosis of Psoriatic Arthritis (PsA, by any criteria) of = 3 months duration.
5. Meet the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria for PsA at time of screening.
6. Have = 3 swollen AND = 3 tender joints.
7. Have not been previously treated with disease-modifying antirheumatic drugs (DMARDS) (small molecules or biologics)
8. Be receiving treatment on an outpatient basis.
9. If taking oral corticosteroids, must be on a stable dose of prednisone = 10 mg/day or equivalent for at least 1 month prior to screening.
10. If taking nonsteroidal anti-inflammatory drugs (NSAIDs) or narcotic analgesics, must be on stable dose for at least 2 weeks prior to screening and until they have completed the Week 24 study visit.
11. Low potency topical corticosteroids (Appendix M or locally available equivalent) will be allowed as background therapy for treatment of psoriasis on the face, axillae and groin in accordance with the manufacturers' suggested usage during the course of the study. Subjects with scalp psoriasis will be permitted to use coal tar shampoo and/or salicylic acid scalp preparations on scalp lesions. A non-medicated skin emollient (eg, Eucerin cream) will also be permitted for body lesions only. Subjects must not use these treatments within 24 hours prior to the clinic visit.
12. Meet the following laboratory criteria:
* White blood cell count = 3000/mm3 (= 3.0 x 109/L) and < 14,000/mm3 (< 14 x 109/L)
* Platelet count = 100,000/mm3 (= 100 x 109/L)
* Serum creatinine = 1.5 mg/dL(= 132.6 µmol/L)
* Aspartate aminotransferase/Serum glutamic oxaloacetic transaminase (AST/SGOT) and Alanine aminotransferase/Serum glutamic pyruvic transaminase (ALT/SGPT) = 2 x upper limit of normal (ULN)
* Total bilirubin = 2 mg/dL (= 34 µmol/L)
* Hemoglobin = 9 g/dL (= 5.6 mmol/L)
* Hemoglobin A1c = 9.0%
13. Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception (latex condom or any nonlatex condom NOT made out of natural [animal] membrane [eg, polyurethane]) while on IP and for at least 28 days after the last dose of IP.
14. Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use 2 forms of contraception while on investigational product (IP) and for at least 28 days after the last dose of IP: one highly effective form (ie, hormonal, intrauterine device [IUD], tubal ligation, vasectomized partner) and one additional form (latex condom or any nonlatex condom NOT made out of natural [animal] membrane [eg, polyurethane], diaphragm, sponge). If one highly effective form of contraception cannot be used, then 2 forms of barrier contraception must be used, ie, latex condom or any nonlatex condom NOT made out of natural (animal) membrane (eg, polyurethane) with either of the following: sponge with spermicide or diaphragm with spermicide.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. History of clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major uncontrolled disease.
2. Any condition, including the presence of laboratory abnormalities that places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
3. Clinically significant abnormality on 12-lead electrocardiography (ECG) at Screening.
4. Pregnant or breast feeding.
5. History of allergy to any component of the IP.
6. Hepatitis B surface antigen positive at screening.
7. Hepatitis C antibody positive at screening.
8. AST/SGOT and/or ALT/SGPT > 1.5 x ULN and total bilirubin > ULN or albumin < lower limit of normal (LLN).
9. History of positive Human Immunodeficiency Virus (HIV), or congenital or acquired immunodeficiency (eg, Common Variable Immunodeficiency Disease).
10. Active tuberculosis or a history of incompletely treated tuberculosis.
11. Clinically significant abnormality based upon chest radiograph with at least PA view (radiograph must be taken within 12 weeks prior to Screening or during the Screening visit). An additional lateral view is strongly recommended but not required.
12. Active substance abuse or a history of substance abuse within 6 months prior to Screening.
13. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening. Any treatment for such infections must have been completed at least 4 weeks prior to Screening.
14. Malignancy or history of malignancy (except for treated [ie, cured] basal cell or squamous cell in situ skin carcinomas and treated [ie, cured] cervical intraepithelial neoplasia [CIN] or carcinoma in situ of the cervix).
15. Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.
16. Erythrodermic, guttate, or pustular psoriasis.
17. Topical therapy for psoriasis, except as noted in the Inclusion Criteria, within 2 weeks of randomization (including but not limited to topical corticosteroids, topical retinoids or vitamin D analog preparations, tacrolimus, pimecrolimus, or anthralin).
18. Rheumatic autoimmune disease other than PsA, including systemic lupus erythematosis (SLE), mixed connective tissue disease (MCTD), scleroderma, or polymyositis.
19. Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis (Appendix Q).
20. Prior history of or current inflammatory joint disease other than PsA (eg, gout, reactive arthritis, RA, ankylosing spondylitis, Lyme disease).
21. Prior use of disease modifying antirheumatic drugs (DMARDS; small molecules or biologics).
22. Use of the following systemic therapy(ies) within 4 weeks of randomization, including but not limited to corticosteroids (except as noted in inclusion criteria), oral retinoids and fumaric acid esters.
23. Use of phototherapy within 4 weeks of randomization (ie, UVB, PUVA).
24. Previous treatment with any cell depleting therapies, including investigational agents (eg, rituximab, CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19, and anti-CD20).
25. Treatment with intravenous gamma globulin, plasmapheresis, or Prosorba® column within 6 months of baseline.
26. Any previous treatment with alkylating agents such as cyclophosphamide or chlorambucil, or with total lymphoid irradiation.
27. Prior treatment with apremilast.
28. Use of any investigational drug within 4 weeks of randomization, or 5 pharmacokinetic/ pharmacodynamic half lives, if known (whichever is longer).
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
9/12/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
16/08/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
529
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Monash Medical Centre - Clayton
Query!
Recruitment hospital [2]
0
0
Eastern Health Clinical School - Box Hill
Query!
Recruitment hospital [3]
0
0
Repatriation General Hospital - Daws Park
Query!
Recruitment hospital [4]
0
0
Menzies Centre for Population Health Research - Hobart
Query!
Recruitment hospital [5]
0
0
Optimus Clinical Research Pty. Ltd - Kogarah
Query!
Recruitment hospital [6]
0
0
The Queen Elizabeth Hospital - Woodville
Query!
Recruitment postcode(s) [1]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [2]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [3]
0
0
5041 - Daws Park
Query!
Recruitment postcode(s) [4]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [5]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [6]
0
0
5011 - Woodville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Idaho
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Indiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Nebraska
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
North Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Pennsylvania
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Tennessee
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Texas
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Wisconsin
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Leuven
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Liège
Query!
Country [19]
0
0
Bulgaria
Query!
State/province [19]
0
0
Plovdiv
Query!
Country [20]
0
0
Bulgaria
Query!
State/province [20]
0
0
Sofia
Query!
Country [21]
0
0
Bulgaria
Query!
State/province [21]
0
0
Varna
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
British Columbia
Query!
Country [23]
0
0
Canada
Query!
State/province [23]
0
0
Manitoba
Query!
Country [24]
0
0
Canada
Query!
State/province [24]
0
0
Newfoundland and Labrador
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Ontario
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Quebec
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Saskatchewan
Query!
Country [28]
0
0
Czechia
Query!
State/province [28]
0
0
Praha 11
Query!
Country [29]
0
0
Czechia
Query!
State/province [29]
0
0
Praha 2
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Praha 4
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Zlin
Query!
Country [32]
0
0
Estonia
Query!
State/province [32]
0
0
Tallinn
Query!
Country [33]
0
0
Estonia
Query!
State/province [33]
0
0
Tartu
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Nantes Cedex 01
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Nice
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Paris Cedex 10
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Paris
Query!
Country [38]
0
0
Hungary
Query!
State/province [38]
0
0
Budapest
Query!
Country [39]
0
0
Hungary
Query!
State/province [39]
0
0
Debrecen
Query!
Country [40]
0
0
Hungary
Query!
State/province [40]
0
0
Kistarcsa
Query!
Country [41]
0
0
Hungary
Query!
State/province [41]
0
0
Mako
Query!
Country [42]
0
0
Hungary
Query!
State/province [42]
0
0
Szolnok
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Genova
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Milano
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Napoli
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Roma
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Verona
Query!
Country [48]
0
0
Korea, Republic of
Query!
State/province [48]
0
0
DaeJeon
Query!
Country [49]
0
0
Korea, Republic of
Query!
State/province [49]
0
0
Incheon
Query!
Country [50]
0
0
Lithuania
Query!
State/province [50]
0
0
Siauliai
Query!
Country [51]
0
0
New Zealand
Query!
State/province [51]
0
0
Hamilton
Query!
Country [52]
0
0
New Zealand
Query!
State/province [52]
0
0
Takapuna
Query!
Country [53]
0
0
New Zealand
Query!
State/province [53]
0
0
Timaru
Query!
Country [54]
0
0
Poland
Query!
State/province [54]
0
0
Bialystok
Query!
Country [55]
0
0
Poland
Query!
State/province [55]
0
0
Bydgoszcz
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Bytom
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Gdynia
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Katowice
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Lublin
Query!
Country [60]
0
0
Poland
Query!
State/province [60]
0
0
Poznan
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Warszawa
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Wroclaw
Query!
Country [63]
0
0
Romania
Query!
State/province [63]
0
0
Bucharest
Query!
Country [64]
0
0
Romania
Query!
State/province [64]
0
0
Cluj-Napoca
Query!
Country [65]
0
0
Romania
Query!
State/province [65]
0
0
Galati
Query!
Country [66]
0
0
Romania
Query!
State/province [66]
0
0
Iasi
Query!
Country [67]
0
0
Russian Federation
Query!
State/province [67]
0
0
Kemerovo
Query!
Country [68]
0
0
Russian Federation
Query!
State/province [68]
0
0
Kezch
Query!
Country [69]
0
0
Russian Federation
Query!
State/province [69]
0
0
Krasnoyarsk
Query!
Country [70]
0
0
Russian Federation
Query!
State/province [70]
0
0
Nizhniy Novgorod
Query!
Country [71]
0
0
Russian Federation
Query!
State/province [71]
0
0
Novosibirsk
Query!
Country [72]
0
0
Russian Federation
Query!
State/province [72]
0
0
Penza
Query!
Country [73]
0
0
Russian Federation
Query!
State/province [73]
0
0
Smolensk
Query!
Country [74]
0
0
Russian Federation
Query!
State/province [74]
0
0
Tomsk
Query!
Country [75]
0
0
Russian Federation
Query!
State/province [75]
0
0
Vladimir
Query!
Country [76]
0
0
Russian Federation
Query!
State/province [76]
0
0
Voronezh
Query!
Country [77]
0
0
Taiwan
Query!
State/province [77]
0
0
Taipei
Query!
Country [78]
0
0
Taiwan
Query!
State/province [78]
0
0
Tapei
Query!
Country [79]
0
0
United Kingdom
Query!
State/province [79]
0
0
Barnsley South Yorkshire
Query!
Country [80]
0
0
United Kingdom
Query!
State/province [80]
0
0
Burslem
Query!
Country [81]
0
0
United Kingdom
Query!
State/province [81]
0
0
Cannock
Query!
Country [82]
0
0
United Kingdom
Query!
State/province [82]
0
0
Poole
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
Southampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis who have not been previously treated with DMARDs. Apremilast is proposed to improve signs and symptoms of psoriatic arthritis (tender and swollen joints, pain, physical function) in treated patients.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01307423
Query!
Trial related presentations / publications
Mease PJ, Kavanaugh A, Ogdie A, Wells AF, Bergman M, Gladman DD, Richter S, Teng L, Jardon S, Smolen JS. Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naive Patients With Psoriatic Arthritis. J Rheumatol. 2022 Jul;49(7):694-699. doi: 10.3899/jrheum.210906. Epub 2022 Apr 15. Wells AF, Edwards CJ, Kivitz AJ, Bird P, Guerette B, Delev N, Paris M, Teng L, Aelion JA. Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naive patients. Rheumatology (Oxford). 2022 Mar 2;61(3):1035-1043. doi: 10.1093/rheumatology/keab449. Wells AF, Edwards CJ, Kivitz AJ, Bird P, Nguyen D, Paris M, Teng L, Aelion JA. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology (Oxford). 2018 Jul 1;57(7):1253-1263. doi: 10.1093/rheumatology/key032.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Query!
Available to whom?
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: http://www.amgen.com/datasharing
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT01307423